NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results Portfolio News / By Karina Tin February 28, 2023 NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results Read More »
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin February 27, 2023 Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress Read More »
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID Portfolio News / By Karina Tin February 21, 2023 eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID Read More »
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy Portfolio News / By Karina Tin February 14, 2023 Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy Read More »
Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules Portfolio News / By Karina Tin February 13, 2023 Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules Read More »
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin February 9, 2023 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update Read More »
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Portfolio News / By Karina Tin February 3, 2023 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read More »
